Compare ALKT & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALKT | GLPG |
|---|---|---|
| Founded | 2007 | 1999 |
| Country | United States | Belgium |
| Employees | N/A | 452 |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.9B |
| IPO Year | 2021 | N/A |
| Metric | ALKT | GLPG |
|---|---|---|
| Price | $15.61 | $28.05 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 2 |
| Target Price | $28.57 | ★ $36.50 |
| AVG Volume (30 Days) | ★ 1.3M | 128.8K |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $152,159,000.00 | N/A |
| Revenue This Year | $21.85 | N/A |
| Revenue Next Year | $16.90 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 35.68 | N/A |
| 52 Week Low | $14.11 | $24.74 |
| 52 Week High | $31.18 | $37.78 |
| Indicator | ALKT | GLPG |
|---|---|---|
| Relative Strength Index (RSI) | 41.73 | 34.12 |
| Support Level | $15.21 | $27.98 |
| Resistance Level | $17.70 | $34.04 |
| Average True Range (ATR) | 0.76 | 0.47 |
| MACD | -0.09 | 0.04 |
| Stochastic Oscillator | 19.27 | 26.41 |
Alkami Technology Inc is a cloud-based digital banking solutions provider. The company offers the Alkami Digital Sales & Service Platform, which includes a digital banking platform, onboarding and account opening solutions, and data and marketing tools. The platform enables financial institutions to onboard and engage users, support revenue growth, and improve operational efficiency through a cloud-based, multi-tenant architecture. The company provides services to clients under software-as-a-service arrangements. It derives substantially all of its revenues from SaaS subscription services charged for the use of digital sales and service solutions.
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, and it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.